These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21685719)

  • 1. 1NM-PP1 treatment of mice infected with Toxoplasma gondii.
    Sugi T; Kato K; Kobayashi K; Kurokawa H; Takemae H; Gong H; Recuenco FC; Iwanaga T; Horimoto T; Akashi H
    J Vet Med Sci; 2011 Oct; 73(10):1377-9. PubMed ID: 21685719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bumped kinase inhibitor 1294 treats established Toxoplasma gondii infection.
    Doggett JS; Ojo KK; Fan E; Maly DJ; Van Voorhis WC
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3547-9. PubMed ID: 24687502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single mutation in the gatekeeper residue in TgMAPKL-1 restores the inhibitory effect of a bumped kinase inhibitor on the cell cycle.
    Sugi T; Kawazu S; Horimoto T; Kato K
    Int J Parasitol Drugs Drug Resist; 2015 Apr; 5(1):1-8. PubMed ID: 25941623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis.
    Hulverson MA; Bruzual I; McConnell EV; Huang W; Vidadala RSR; Choi R; Arnold SLM; Whitman GR; McCloskey MC; Barrett LK; Rivas KL; Scheele S; DeRocher AE; Parsons M; Ojo KK; Maly DJ; Fan E; Van Voorhis WC; Doggett JS
    J Infect Dis; 2019 Apr; 219(9):1464-1473. PubMed ID: 30423128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of mutations in TgMAPK1 of Toxoplasma gondii conferring resistance to 1NM-PP1.
    Sugi T; Kobayashi K; Takemae H; Gong H; Ishiwa A; Murakoshi F; Recuenco FC; Iwanaga T; Horimoto T; Akashi H; Kato K
    Int J Parasitol Drugs Drug Resist; 2013 Dec; 3():93-101. PubMed ID: 24533298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.
    Vidadala RS; Rivas KL; Ojo KK; Hulverson MA; Zambriski JA; Bruzual I; Schultz TL; Huang W; Zhang Z; Scheele S; DeRocher AE; Choi R; Barrett LK; Siddaramaiah LK; Hol WG; Fan E; Merritt EA; Parsons M; Freiberg G; Marsh K; Kempf DJ; Carruthers VB; Isoherranen N; Doggett JS; Van Voorhis WC; Maly DJ
    J Med Chem; 2016 Jul; 59(13):6531-46. PubMed ID: 27309760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two old drugs, NVP-AEW541 and GSK-J4, repurposed against the Toxoplasma gondii RH strain.
    Liu S; Wu M; Hua Q; Lu D; Tian Y; Yu H; Cheng L; Chen Y; Cao J; Hu X; Tan F
    Parasit Vectors; 2020 May; 13(1):242. PubMed ID: 32393321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis.
    Müller J; Aguado-Martínez A; Ortega-Mora LM; Moreno-Gonzalo J; Ferre I; Hulverson MA; Choi R; McCloskey MC; Barrett LK; Maly DJ; Ojo KK; Van Voorhis W; Hemphill A
    J Antimicrob Chemother; 2017 Aug; 72(8):2334-2341. PubMed ID: 28486633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors.
    Ojo KK; Larson ET; Keyloun KR; Castaneda LJ; Derocher AE; Inampudi KK; Kim JE; Arakaki TL; Murphy RC; Zhang L; Napuli AJ; Maly DJ; Verlinde CL; Buckner FS; Parsons M; Hol WG; Merritt EA; Van Voorhis WC
    Nat Struct Mol Biol; 2010 May; 17(5):602-7. PubMed ID: 20436472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with Bumped Kinase Inhibitor 1294 Is Safe and Leads to Significant Protection against Abortion and Vertical Transmission in Sheep Experimentally Infected with Toxoplasma gondii during Pregnancy.
    Sánchez-Sánchez R; Ferre I; Re M; Ramos JJ; Regidor-Cerrillo J; Pizarro Díaz M; González-Huecas M; Tabanera E; Benavides J; Hemphill A; Hulverson MA; Barrett LK; Choi R; Whitman GR; Ojo KK; Van Voorhis WC; Ortega-Mora LM
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the kinase inhibitor analog 1NM-PP1 reveals a role for Toxoplasma gondii CDPK1 in the invasion step.
    Sugi T; Kato K; Kobayashi K; Watanabe S; Kurokawa H; Gong H; Pandey K; Takemae H; Akashi H
    Eukaryot Cell; 2010 Apr; 9(4):667-70. PubMed ID: 20173034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effect of lactoferricin against Toxoplasma gondii infection in mice.
    Isamida T; Tanaka T; Omata Y; Yamauchi K; Shimazaki K; Saito A
    J Vet Med Sci; 1998 Feb; 60(2):241-4. PubMed ID: 9524950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-10 is not required to prevent immune hyperactivity during memory responses to Toxoplasma gondii.
    Wille U; Nishi M; Lieberman L; Wilson EH; Roos DS; Hunter CA
    Parasite Immunol; 2004 May; 26(5):229-36. PubMed ID: 15491472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum.
    Winzer P; Müller J; Aguado-Martínez A; Rahman M; Balmer V; Manser V; Ortega-Mora LM; Ojo KK; Fan E; Maly DJ; Van Voorhis WC; Hemphill A
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6361-74. PubMed ID: 26248379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Nigella sativa oil on experimental toxoplasmosis.
    Mady RF; El-Hadidy W; Elachy S
    Parasitol Res; 2016 Jan; 115(1):379-90. PubMed ID: 26446086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1 decrease the parasite burden in mice with acute toxoplasmosis.
    Moine E; Moiré N; Dimier-Poisson I; Brunet K; Couet W; Colas C; Van Langendonck N; Enguehard-Gueiffier C; Gueiffier A; Héraut B; Denevault-Sabourin C; Debierre-Grockiego F
    Int J Parasitol; 2018 Jun; 48(7):561-568. PubMed ID: 29524527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulfamethoxazole-trimethoprim associated with resveratrol for the treatment of toxoplasmosis in mice: Influence on the activity of enzymes involved in brain neurotransmission.
    Bottari NB; Baldissera MD; Tonin AA; Rech VC; Nishihira VS; Thomé GR; Schetinger MR; Morsch VM; Camillo G; Vogel FF; Tochetto C; Fighera R; Machado G; Stefani LM; Da Silva AS
    Microb Pathog; 2015 Feb; 79():17-23. PubMed ID: 25572158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage conversion of Toxoplasma gondii RH parasites in mice by treatment with atovaquone and pyrrolidine dithiocarbamate.
    Djurković-Djaković O; Nikolić A; Bobić B; Klun I; Aleksić A
    Microbes Infect; 2005 Jan; 7(1):49-54. PubMed ID: 15716077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Calcium-Dependent Protein Kinase 1 Inhibitor Potently Prevents
    Débare H; Moiré N; Baron F; Lantier L; Héraut B; Van Langendonck N; Denevault-Sabourin C; Dimier-Poisson I; Debierre-Grockiego F
    Molecules; 2021 Jul; 26(14):. PubMed ID: 34299478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibition of Sarcocystis neurona calcium-dependent protein kinase 1 for equine protozoal myeloencephalitis therapy.
    Ojo KK; Dangoudoubiyam S; Verma SK; Scheele S; DeRocher AE; Yeargan M; Choi R; Smith TR; Rivas KL; Hulverson MA; Barrett LK; Fan E; Maly DJ; Parsons M; Dubey JP; Howe DK; Van Voorhis WC
    Int J Parasitol; 2016 Dec; 46(13-14):871-880. PubMed ID: 27729271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.